Sartorius Stedim Biotech : Relèvement des guidances 2020 – Projections et OC relevés – Neutre vs Achat
>Upgrade des guidances 2020 - Devançant ses annonces du 21 juillet (S1 2020), Sartorius Stedim Biotech a indiqué hier soir qu’il visait désormais pour 2020 une croissance des ventes de 26 à 30% (contre 17 à 21% auparavant) et une marge d’EBITDA courant d'environ 31% (contre 30% auparavant).En effet, sur la base du S1 2020 (Prises de commandes : +34.1% - CA à tcc.: +22% - marge d’EBITDA courant : 30.2%), SSB revoit en hausse ses prévisions, malgré le contexte COVI...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.